Senseonics (NYSEAMERICAN:SENS) Downgraded by Canaccord Genuity to “Hold”

Share on StockTwits

Canaccord Genuity lowered shares of Senseonics (NYSEAMERICAN:SENS) from a buy rating to a hold rating in a report issued on Wednesday morning, The Fly reports. They currently have $1.00 target price on the stock, down from their prior target price of $2.00.

A number of other research analysts have also commented on the stock. Stifel Nicolaus started coverage on shares of Senseonics in a research report on Tuesday, October 22nd. They set a buy rating and a $2.00 price target for the company. BTIG Research restated a buy rating and set a $2.00 price target on shares of Senseonics in a research report on Sunday, August 11th. Finally, Piper Jaffray Companies set a $2.00 price target on shares of Senseonics and gave the company a hold rating in a research report on Wednesday, September 4th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. Senseonics currently has an average rating of Hold and a consensus target price of $1.90.

Shares of SENS traded down $0.01 during mid-day trading on Wednesday, reaching $0.87. 1,516,045 shares of the stock traded hands, compared to its average volume of 1,759,505. The firm has a fifty day moving average price of $1.07 and a 200 day moving average price of $1.79. Senseonics has a 1 year low of $0.80 and a 1 year high of $3.60.

In related news, CEO Timothy T. Goodnow bought 88,500 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was bought at an average cost of $1.10 per share, for a total transaction of $97,350.00. 34.10% of the stock is currently owned by insiders.

A number of large investors have recently made changes to their positions in the stock. Bank of Montreal Can lifted its stake in Senseonics by 236.4% in the second quarter. Bank of Montreal Can now owns 14,513 shares of the company’s stock worth $29,000 after purchasing an additional 10,199 shares during the last quarter. D. E. Shaw & Co. Inc. bought a new stake in Senseonics in the second quarter worth $33,000. Centaurus Financial Inc. lifted its stake in Senseonics by 40,551.2% in the second quarter. Centaurus Financial Inc. now owns 16,667 shares of the company’s stock worth $34,000 after purchasing an additional 16,626 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Senseonics by 3.9% in the second quarter. Charles Schwab Investment Management Inc. now owns 515,464 shares of the company’s stock worth $1,052,000 after purchasing an additional 19,330 shares during the last quarter. Finally, Commonwealth Equity Services LLC lifted its stake in Senseonics by 194.0% in the third quarter. Commonwealth Equity Services LLC now owns 29,664 shares of the company’s stock worth $29,000 after purchasing an additional 19,574 shares during the last quarter. Institutional investors own 30.66% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.

Recommended Story: Growth Stocks

The Fly

Analyst Recommendations for Senseonics (NYSEAMERICAN:SENS)

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

BZEdge Price Hits $0.0001 on Top Exchanges
BZEdge Price Hits $0.0001 on Top Exchanges
Fortive  Upgraded to “Outperform” at Credit Suisse Group
Fortive Upgraded to “Outperform” at Credit Suisse Group
Vertex Energy  Research Coverage Started at HC Wainwright
Vertex Energy Research Coverage Started at HC Wainwright
Fate Therapeutics  Raised to “Outperform” at Wells Fargo & Co
Fate Therapeutics Raised to “Outperform” at Wells Fargo & Co
Edwards Lifesciences’  Overweight Rating Reiterated at Piper Jaffray Companies
Edwards Lifesciences’ Overweight Rating Reiterated at Piper Jaffray Companies
Virgin Galactic  Earns Overweight Rating from Analysts at Morgan Stanley
Virgin Galactic Earns Overweight Rating from Analysts at Morgan Stanley


© 2006-2019 Ticker Report